Journal article
Safety of artemisinins in first trimester of prospectively followed pregnancies: An observational study
KA Moore, JA Simpson, MK Paw, MPJ Pimanpanarak, J Wiladphaingern, MJ Rijken, P Jittamala, NJ White, FJI Fowkes, F Nosten, R McGready
Lancet Infectious Diseases | Published : 2016
Abstract
Background: Artemisinins, the most effective antimalarials available, are not recommended for falciparum malaria during the first trimester of pregnancy because of safety concerns. Therefore, quinine is used despite its poor effectiveness. Assessing artemisinin safety requires weighing the risks of malaria and its treatment. We aimed to assess the effect of first-trimester malaria and artemisinin treatment on miscarriage and major congenital malformations. Methods: In this observational study, we assessed data from antenatal clinics on the Thai-Myanmar border between Jan 1, 1994, and Dec 31, 2013. We included women who presented to antenatal clinics during their first trimester with a viable..
View full abstractGrants
Awarded by Australian Research Council
Funding Acknowledgements
Funding for the Ebola Vaccine Team B is provided by the Wellcome Trust, UK. The authors also acknowledge Carlos R Cruz (CIDRAP, University of Minnesota, Minneapolis, MN, USA) for project management related to the Ebola Vaccine Team B.